OncoMatch/Clinical Trials/NCT06964009
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Official title: A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Is NCT06964009 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including DT2216 and Paclitaxel for ovarian cancer.
Treatment: DT2216 · Paclitaxel — The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — primary management of disease
Participants must have received at least one prior platinum-based chemotherapeutic regimen for primary management of disease.
Cannot have received: BCL-XL inhibitor (navitoclax)
Prior treatment with any BCL-XL inhibitor, such as navitoclax.
Lab requirements
Blood counts
absolute neutrophil count ≥1000/mcL; platelets ≥100,000/mcL; hemoglobin ≥8 g/dL
Kidney function
Exact limits: see the full eligibility criteria on this page.
Liver function
Exact limits: see the full eligibility criteria on this page.
Cardiac function
Baseline prolongation of QTc interval (3e 470 msec) using Bazett's formula or history of Long QT Syndrome excluded
Exact limits: see the full eligibility criteria on this page.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center (BIDMC) · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
- Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06964009 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL-XL inhibitor disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages